{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T14:00:42Z","timestamp":1776693642838,"version":"3.51.2"},"reference-count":72,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.clinthera.2025.01.009","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T12:19:33Z","timestamp":1739449173000},"page":"e12-e20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of First-line Targeted Therapies in Physically Fit Patients With Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6315-681X","authenticated-orcid":false,"given":"Anita","family":"Sto\u017cek-Tutro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Reczek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawe\u0142","family":"Kawalec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.01.009_bib0001","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0002","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): An international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0003","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0004","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Chronic lymphocytic leukemia\/small lymphocytic lymphoma. Version 1.2024. www.nccn.org\/patients. Accessed December 28, 2023."},{"key":"10.1016\/j.clinthera.2025.01.009_bib0005","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1182\/blood.2023020158","article-title":"Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up","volume":"142","author":"Thompson","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0006","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1182\/blood-2021-152319","article-title":"Ibrutinib plus rituximab is superior to FCR in previously untreated CLL: Results of the phase III NCRI FLAIR trial","volume":"138","author":"Hillmen","year":"2021","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2025.01.009_bib0007","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0008","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: Updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0009","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1470-2045(23)00144-4","article-title":"Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): Interim analysis of a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Hillmen","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0010","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0011","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0012","unstructured":"Sto\u017cek-Tutro A, Kawalec P. PROSPERO - Protocol. 2023. https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=393903. Accessed December 28, 2023."},{"key":"10.1016\/j.clinthera.2025.01.009_bib0013","unstructured":"Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. robvis - a web app designed to for visualizing risk-of-bias assessments performed as part of a systematic review. https:\/\/www.riskofbias.info\/welcome\/robvis-visualization-tool. Accessed December 28, 2023."},{"key":"10.1016\/j.clinthera.2025.01.009_bib0014","unstructured":"Dias S, Welton N, Sutton A, Ades A. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. https:\/\/www.sheffield.ac.uk\/media\/34176\/download?attachment. Accessed December 28, 2023."},{"key":"10.1016\/j.clinthera.2025.01.009_bib0015","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1023\/A:1008929526011","article-title":"WinBUGS - a Bayesian modelling framework: Concepts, structure, and extensibility","volume":"10","author":"Lunn","year":"2000","journal-title":"Stat Comput"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0016","unstructured":"European Medicines Agency. Summary of product characteristics. https:\/\/www.ema.europa.eu\/documents\/product-information\/imbruvica-epar-product-information_en.pdf. Accessed July 1, 2023."},{"key":"10.1016\/j.clinthera.2025.01.009_bib0017","unstructured":"European Medicines Agency. Assessment report - Imbruvica. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/imbruvica-h-c-3791-ii-0059-epar-assessment-report-variation_en.pdf. Accessed XXX."},{"key":"10.1016\/j.clinthera.2025.01.009_bib0018","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib\u2013rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0019","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1182\/blood.2020010146","article-title":"Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib","volume":"138","author":"Wang","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0020","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1182\/blood.V128.22.4373.4373","article-title":"Novel associations between mutations, prognostic and clinical parameters in untreated progressive CLL: Data from E1912, a randomized phase III study of the ECOG-ACRIN Cancer Research Group","volume":"128","author":"Braggio","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0021","first-page":"4288","volume":"130","author":"Braggio","year":"2017","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2025.01.009_bib0022","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1182\/blood-2018-99-118333","volume":"132","author":"Papazoglou","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2025.01.009_bib0023","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2021-150462","article-title":"Quality of life in patients \u226470 years of age with chronic lymphocytic leukemia treated frontline with ibrutinib-rituximab versus fludarabine cyclophosphamide rituximab: Analysis from ECOG-ACRIN E1912","volume":"138","author":"Pophali","year":"2021","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2025.01.009_bib0024","volume":"132","author":"Shanafelt","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2025.01.009_bib0025","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2019-126824","article-title":"Ibrutinib and rituximab provides superior clinical outcome compared to FCR in younger patients with chronic lymphocytic leukemia (CLL): Extended follow-up from the E1912 trial","volume":"134","author":"Shanafelt","year":"2019","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2025.01.009_bib0026","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1182\/blood-2021-145624","article-title":"Preliminary results of the filo phase 2 trial for untreated fit patients with intermediate risk chronic lymphocytic leukemia comparing ibrutinib plus venetoclax (IV) versus FCR","volume":"138","author":"Michallet","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0027","first-page":"S86","article-title":"Preliminary results of the FILO phase 2 trial for untreated fit patients with intermediate risk chronic lymphocytic leukemia comparing ibrutinib plus venetoclax (IV) versus FCR","volume":"62","author":"Michallet","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2025.01.009_bib0028","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.1182\/blood-2022-159678","article-title":"Preliminary results of the Filo phase 2 trial for untreated fit patients with intermediate risk chronic lymphocytic leukemia comparing ibrutinib plus venetoclax (IV) versus FCR: results of the month 15 MRD evaluation","volume":"140","author":"Quinquenel","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0029","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1182\/blood-2021-152167","article-title":"Sudden or cardiac deaths on ibrutinib-based therapy were associated with a prior history of hypertension or cardiac disease and the use of ACE-inhibitors at study entry: analysis from the phase III NCRI FLAIR trial","volume":"138","author":"Munir","year":"2021","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2025.01.009_bib0030","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1182\/blood-2021-152167","article-title":"Sudden or cardiac deaths on ibrutinib-based therapy were associated with a prior history of hypertension or cardiac disease and the use of ACE-inhibitors at study entry: analysis from the phase III NCRI FLAIR trial","volume":"138","author":"Munir","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0031","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13063-020-04971-2","article-title":"A platform trial in practice: adding a new experimental research arm to the ongoing confirmatory FLAIR trial in chronic lymphocytic leukaemia","volume":"22","author":"Howard","year":"2021","journal-title":"Trials"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0032","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1186\/s13063-017-2138-6","article-title":"Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial","volume":"18","author":"Collett","year":"2017","journal-title":"Trials"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0033","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1182\/blood.V112.11.326.326","article-title":"Quantitative MRD assessments predict progression free survival in CLL patients treated with fludarabine and cyclophosphamide with or without rituximab \u2013 a prospective analysis in 471 patients from the randomized GCLLSG CLL8 trial","volume":"112","author":"Boettcher","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0034","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","article-title":"Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial","volume":"30","author":"B\u00f6ttcher","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0035","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1182\/blood.V114.22.3438.3438","volume":"114","author":"Eichhorst","year":"2009","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2025.01.009_bib0036","doi-asserted-by":"crossref","first-page":"S230","DOI":"10.1016\/j.clml.2011.09.139","article-title":"4.19 Prediction of poor outcome in chronic lymphocytic leukemia patients treated with FCR (fludarabine, cyclophosphamide, rituximab) in the CLL8 trial of the German CLL Study Group","volume":"11","author":"Fink","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0037","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V120.21.435.435","volume":"120","author":"Fischer","year":"2012","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clinthera.2025.01.009_bib0038","first-page":"86","article-title":"Long term remissions after FCR chemoimmunotherapy in patients with CLL","volume":"37","author":"Fischer","year":"2014","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0039","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/blood.V114.22.535.535","volume":"114","author":"Hallek","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0040","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/10428194.2016.1190966","article-title":"FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia","volume":"58","author":"Kutsch","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0041","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1182\/blood.V124.21.1938.1938","article-title":"Subclonal driver mutations predict shorter progression free survival in chronic lymphocytic leukemia following first-line chemo(immuno)therapy: results from the CLL8 trial","volume":"124","author":"Landau","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0042","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1586\/era.11.118","article-title":"Progress in the treatment of chronic lymphocytic leukemia: results of the German CLL8 trial","volume":"11","author":"Molica","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0043","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/blood.V114.22.1267.1267","article-title":"TP53 mutations and outcome after fludarabine and cyclophosphamide (FC) or FC plus rituximab (FCR) in the CLL8 trial of the GCLLSG","volume":"114","author":"Zenz","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0044","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1182\/blood.V118.21.2863.2863","article-title":"Second-line therapies after treatment with fludarabine, cyclophosphamide, and rituximab (FCR) or fludarabine and cyclophosphamid alone (FC) for chronic lymphocytic leukemia (CLL) within the CLL8-protocol of the German CLL Study Group (GCLLSG)","volume":"118","author":"Cramer","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0045","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1182\/blood.V122.21.526.526","volume":"122","author":"Eichhorst","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0046","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood.V124.21.19.19","volume":"124","author":"Eichhorst","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0047","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1182\/blood.V128.22.4382.4382","volume":"128","author":"Eichhorst","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0048","first-page":"3021","article-title":"Prognostic impact of immunohistochemistry and MRD results in bone marrow after frontline chemoimmunotherapy of chronic lymphocytic leukemia (CLL): Results of central laboratory analyses of the CLL10 trial of the German CLL Study Group (GCLLSG)","volume":"130","author":"Kutsch","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0049","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.1097\/HS9.0000000000000336","article-title":"Long term follow-up data and health-related quality of life in frontline therapy of fit patients treated with FCR versus BR (CLL10 Trial of the GCLLSG)","volume":"4","author":"Kutsch","year":"2020","journal-title":"Hemasphere"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0050","first-page":"185","article-title":"More severe infectious complications in CLL patients treated with fludarabine, cyclophosphamide, rituximab (FCR) in comparison to bendamustin plus rituximab (BR): Results of the interim-analysis of the CLL10 trial of the German CLL Study Group","volume":"37","author":"Langerbeins","year":"2014","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0051","first-page":"55","article-title":"Severe infections are more common in physically fit CLL patients with FCR-therapy compared to BR: Results of the intermin-analysis of the CLL10 trial of the German CLL Study Group","volume":"99","author":"Langerbeins","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0052","unstructured":"EU Clinical Trials Register. Phase III trial of combined immunochemotherapy with fludarabine, cyclophosphamide and rituximab (FCR) versus bendamustine and rituximab (BR) in patients with previously untreated chronic lymphocytic leukemia. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/rest\/download\/result\/zip\/pdf\/2007-007587-21\/1. Accessed July 1, 2023."},{"key":"10.1016\/j.clinthera.2025.01.009_bib0053","unstructured":"ClinicalTrials.gov. Fludarabine and cyclophosphamide with or without rituximab in patients with previously untreated chronic B-cell lymphocytic leukemia (CLL-8. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00281918. Accessed July 1, 2023."},{"issue":"Suppl 6","key":"10.1016\/j.clinthera.2025.01.009_bib0054","first-page":"142","article-title":"Data quality improvement by a screening process within the CLL10 trial of the German CLL Study Group evaluating combined chemoimmunotherapy in first line treatment of chronic lymphocytic leukemia","volume":"34","author":"Cramer","year":"2011","journal-title":"Onkologie"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2025.01.009_bib0055","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2021-146161","volume":"138","author":"Eichhorst","year":"2021","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2025.01.009_bib0056","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2021-147790","article-title":"Comparison of tumor lysis syndrome (TLS) risk reduction and incidence in different venetoclax-based combinations within the randomized phase 3 GAIA (CLL13) trial","volume":"138","author":"F\u00fcrstenau","year":"2021","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2025.01.009_bib0057","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1182\/blood-2021-147729","article-title":"High resolution assessment of minimal residual disease (MRD) by next-generation sequencing (NGS) and high-sensitivity flow cytometry (hsFCM) in the phase 3 GAIA (CLL13) trial","volume":"138","author":"F\u00fcrstenau","year":"2021","journal-title":"Blood"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2025.01.009_bib0058","doi-asserted-by":"crossref","first-page":"TPS7582","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS7582","article-title":"The GAIA (CLL13) trial: an international intergroup phase III study for frontline therapy in chronic lymphocytic leukemia (CLL)","volume":"36","author":"Julia","year":"2018","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2025.01.009_bib0059","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1097\/01.HS9.0000850364.78915.d9","article-title":"PB1878: Cross-trial analysis of fixed-duration ibrutinib (I) plus venetoclax (V) vs fludarabine (F), cyclophosphamide (C), and rituximab (R) as first-line treatment for chronic lymphocytic leukemia (CLL)","volume":"6","author":"Barrientos","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0060","unstructured":"ClinicalTrial.gov. Ibrutinib plus venetoclax in subjects with treatment-naive chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) (Captivate). https:\/\/www.clinicaltrials.gov\/study\/NCT02910583#publications. Accessed July 1, 2023."},{"key":"10.1016\/j.clinthera.2025.01.009_bib0061","unstructured":"European Medicines Agency. Guideline on the clinical evaluation of anticancer medicinal products. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-evaluation-anticancer-medicinal-products-revision-6_en.pdf. Accessed December 28, 2023."},{"key":"10.1016\/j.clinthera.2025.01.009_bib0062","unstructured":"European Medicines Agency. Appendix 4 to the guideline on the evaluation of anticancer medicinal products in man. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/evaluation-anticancer-medicinal-products-man-appendix-4-condition-specific-guidance-revision-2_en.pdf. Accessed December 28, 2023."},{"key":"10.1016\/j.clinthera.2025.01.009_bib0064","first-page":"2","article-title":"The role of minimal residual disease (MRD) and fixed time duration (FTD) on the example of venetoclax in chronic lymphocytic leukemia (CLL) - clinical and systemic perspective","volume":"2","author":"Kordecki","year":"2020","journal-title":"JHPOR"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0065","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11912-023-01482-6","article-title":"Chronic lymphocytic leukemia: Time-limited therapy in the first-line setting and role of minimal residual disease","volume":"26","author":"Stumpf","year":"2024","journal-title":"Curr Oncol Rep"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2025.01.009_bib0066","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood-2023-178597","article-title":"Endpoint surrogacy in chronic lymphocytic leukemia: A pooled analysis of the German CLL Study Group","volume":"142","author":"Simon","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0063","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2024.2122","article-title":"Measurable residual disease and clinical outcomes in chronic lymphocytic leukemia: A systematic review and meta-analysis","volume":"10","author":"Rios-Olais","year":"2024","journal-title":"JAMA Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2025.01.009_bib0067","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1182\/blood-2022-156070","article-title":"Residual disease kinetics among patients with high-risk factors treated with first-line fixed-duration ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O): The Glow study","volume":"140","author":"Niemann","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0068","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0069","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0070","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0071","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax\u2013rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.01.009_bib0072","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104428","article-title":"Safety profile of first-line targeted therapies in elderly and\/or comorbid chronic lymphocytic leukaemia patients (unfit subpopulation). A systematic review and network meta-analysis","volume":"201","author":"Sto\u017cek-Tutro","year":"2024","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825000104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825000104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T12:35:05Z","timestamp":1744202105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825000104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":72,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0149291825000104"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.01.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of First-line Targeted Therapies in Physically Fit Patients With Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}